1 |
In vitro aerodynamic characterization of the dose emitted during nebulization of tobramycin high strength solution by novel and jet nebulizer delivery systemsMashat, M., Clark, Brian J., Assi, Khaled H., Chrystyn, Henry 30 December 2015 (has links)
Yes / Background: Chronic infections with Pseudomonas aeruginosa are a leading cause of morbidity in patients
with cystic fibrosis (CF). The aim of tobramycin inhalation therapy in CF patients with chronic pulmonary
infection is to deliver high amounts of drug directly to the site of infection. TOBI® is a tobramycin
nebulizer solution (300 mg/5 ml) approved by FDA for maintenance therapy for patient with CF. The 20%
tobramycin sulfate solution was reported as the optimal and maximal concentration.
Methods: Nebulization of high strength tobramycin solution (20% tobramycin sulfate) (HSTS) has been
assessed in this study by using different selected high performance nebulizer delivery systems: two
different designs of jet nebulizers, and three new nebulizers based on vibrating mesh technology. The
aerosol particle size distribution and output characteristics were measured for in vitro performance
assessment of the nebulizer systems. The methodology was adapted from the current European standard,
EN 13544-1:2001E.
Results: The particle size distribution characteristic measurements showed that all tested nebulizers may
be suitable for inhalation of HSTS. The mean (SD) of highest percentage of fine particles (<5 mm) was
77.64 (2.3) % for Sidestream®, at flow rate 16 L/min. The highest respirable inhaled mass was for Pari LC
Plus® combined with PariBoyN® compressor, with mean (SD) 90.85 (8.6) mg. The mean (SD) of highest
drug wastage percentage was 63.9 (3.9) % for Sidestream® jet nebulizer combined with compressed air
cylinder at flow rate 16 L/min, while the lowest was 2.3 (0.26) % for NE-U22 Omron® (high frequency).
Conclusions: The HSTS can be nebulized by all tested nebulisers but the high frequency NE-U22 Omron®
and Aeroneb Go® are more efficient. When the HSTS compared to TOBI®, the respirable inhaled dose was
increased to more than 73%.
|
2 |
Stanovení tržní hodnoty podniku / Determination market value of companyBRÁZDOVÁ, Nela January 2013 (has links)
The aim of diploma thesis is to evaluate selected company as a whole for its inner purpose. This purpose allocate category value, respectively determination of venture?s market value, which is most often defined as estimated amount for shift assets to the date of evaluation among optional and independent partners. Theoretical part of thesis qualify theoretical problem frame of company valuation. In this part of thesis essential key words, factors and value categories are defined. Part of the problem is also strategic and financial analysis and projection of future reports or financial plan. Last part deals with methods of valuation itself ? methods based on revenue analysis, market and assets. For evaluation purpose has been chosen company BRÁZDA-AUDIT, a. s., which deals with experts activities in field of economics.
|
Page generated in 0.0347 seconds